Use of soluble cytokeratin-1-fragments in diagnostics and therapy
OwnerAndreas Bergmann, Joachim Struck +1inventors
InventorsAndreas Bergmann, Joachim Struck, Monika Ühlein
Life of this patent
Estimating the term…
Abstract
Use of novel soluble cytokeratin 1 fragments from body fluids or body tissues as marker peptides for the diagnosis, prognosis and monitoring of the course of inflammations and infections and/or as a target for the therapeutic influencing of the course of inflammations and/or infections.
Claims7
A method for diagnosis of systemic inflammation and/or systemic infection in an animal or patient, comprising testing a biological sample from said animal or patient for the presence of a soluble cytokeratin 1 fragment or soluble cytokeratin 1 fragments, wherein the soluble cytokeratin 1 fragment consists of the amino acid sequence of amino acids 151–510 of the complete amino acid sequence of cytokeratin 1 (SEQ ID NO:
- 3) or the soluble cytokeratin 1 fragment has a molecular weight, as determined by gel electrophoresis of, 15,700±500 Dalton, has an amino acid sequence comprising amino acids 185–297 (SEQ ID NO:
- 5) of the complete amino acid sequence of cytokeratin 1 (SEQ ID NO:
- 3) and one or more additional amino acids at one or both ends of SEQ ID NO:
- 5 for a total of up to 20 adjacent amino acids of the complete amino acid sequence of cytokeratin 1 and wherein the presence of said fragment or fragments is indicative of the presence of sepsis, sepsis-like systemic inflammation and/or infection.
Dependencies are inferred from the claim text.